Cogent Biosciences Stock Soars: A Year of Gains and a $4.5M Sell
Cogent Biosciences has delivered staggering gains in a single year, yet a major fund recently trimmed its stake by mi...
Identify the most severe drawdowns in index fund history and review their recovery paths to inform risk management.
16,017 articlesCogent Biosciences has delivered staggering gains in a single year, yet a major fund recently trimmed its stake by mi...
When the Doctor Who 2026 Christmas special was canceled, fans faced more than a calendar change. This article transla...
A major fund trims a big stake in a tech name, sparking questions about risk, sector exposure, and portfolio resilien...
When a pop moment turns personal, fans feel the emotion—and the money questions that follow. This piece translates th...
When a prominent hedge fund reports selling a large block of shares, it sparks questions about the stock’s future. Th...
A high-profile moment in the stands becomes a lesson in how we spend on experiences. Learn practical ways to budget f...
A decade of dividend growth and a tiny fee have made the Vanguard Dividend Appreciation ETF a standout for risk-aware...
A late-night joke becomes a financial brain-teaser: how the trillionaire milestone reframes wealth and what it means ...
A high-profile White House move puts Silicon Valley on center stage. As trump appoints mark zuckerberg to a new scien...
Berkshire Hathaway's Greg Abel could be quietly steering a strategic tilt toward AI-enabled winners. This deep dive e...
One investor started with a single rental six years ago and now closes about 24 deals each year. This story breaks do...
Celebrity headlines grab attention, but the real story is how money moves in the face of uncertainty. This guide tran...